venBio Partners LLC Acquires Shares of 12,884,638 ALX Oncology Holdings Inc. $ALXO

venBio Partners LLC bought a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 12,884,638 shares of the company’s stock, valued at approximately $26,671,201. ALX Oncology accounts for 0.0% of venBio Partners LLC’s portfolio, making the stock its 5th largest position. venBio Partners LLC owned approximately 9.32% of ALX Oncology at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Callan Family Office LLC bought a new stake in shares of ALX Oncology in the second quarter valued at about $46,000. Invesco Ltd. bought a new stake in shares of ALX Oncology in the 1st quarter worth approximately $46,000. The Manufacturers Life Insurance Company purchased a new position in ALX Oncology in the 2nd quarter worth $64,000. Bridgeway Capital Management LLC bought a new position in ALX Oncology in the 3rd quarter worth about $66,000. Finally, AQR Capital Management LLC raised its stake in ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after purchasing an additional 77,065 shares during the period. 97.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ALXO shares. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.60.

ALX Oncology Price Performance

ALXO stock traded down $0.05 during midday trading on Friday, reaching $2.00. The stock had a trading volume of 639,790 shares, compared to its average volume of 1,024,666. ALX Oncology Holdings Inc. has a 52-week low of $0.96 and a 52-week high of $2.66. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The company’s fifty day simple moving average is $2.00 and its 200 day simple moving average is $1.97. The company has a market cap of $276.56 million, a price-to-earnings ratio of -1.77 and a beta of 0.42.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. As a group, sell-side analysts predict that ALX Oncology Holdings Inc. will post -0.6 earnings per share for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.